Arvinas Oncology Medical

BCL6 plays a crucial role in NHL, particularly in diffuse large B-cell lymphoma (DLBCL). As a transcriptional repressor it regulates germinal center formation and B-cell maturation. However, when dysregulated, BCL6 drives lymphomagenesis, contributing to the development and progression of NHL. Understanding the role of BCL6 is essential for deepening our knowledge of lymphoma and driving the development of new therapeutic strategies. Learn about a recruiting clinical trial for an investigational #PROTAC BCL6 degrader here: http://bit.ly/3ND23rW #Hematology #Oncology #lymsm

The #ScienceofPROTACs: Part 1 – Targeted Protein Degradation Over the next three weeks, we’re sharing a series of short videos explaining the unique mechanism of action behind our PROTAC platform. Stay tuned as we break it down step by step! In Part 1, we explore how PROTACs harness the body’s natural protein disposal system, the ubiquitin-proteasome system (UPS) to selectively target and degrade disease-causing proteins. Watch a short video to see how the UPS works and learn more about #PROTAC science here: http://bit.ly/47x6RbN Watch now and check back next week for Part 2! #HCPs #TPD #CancerResearch

ER+/HER2- breast cancer is the most common subtype of breast cancer, accounting for ~70% of cases. First-line treatment for advanced or metastatic disease typically includes endocrine therapy + a CDK4/6 inhibitor. However, resistance to treatment inevitably emerges leading to disease progression and poor outcomes for patients. New treatments options are urgently needed. #BreastCancer #Oncology #bscm 

#HCPs Interested in exploring #ClinicalTrials involving #PROTACs? Using the ubiquitin-proteasome system (UPS), #PROTACs can selectively target and degrade disease-causing proteins. Learn about ongoing clinical trials with PROTACs here: https://lnkd.in/gueHx8as #TPD #clinicaltrials

#NEWS: Together with Pfizer, we’re pleased to announce positive topline progression-free survival results from a Phase 3 clinical trial in adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic #BreastCancer whose tumors harbor ESR mutations.   We’re encouraged by these results and the potential to help address an unmet need for breast cancer patients, reinforcing our commitment to drive innovation in the field of oncology. Read more: https://bit.ly/43AR8bq

PROTACs offer a novel approach to selectively degrade specific proteins, opening new approaches for therapeutic interventions. Learn more about #PROTAC science at http://bit.ly/47x6RbN #HCPs #TPD #CancerResearch

Arvinas is proud to sponsor Living Beyond Breast Cancer's 19th Annual Conference on Metastatic Breast Cancer. This program provides a weekend of information, inspiration, and connection. Learn more about the conference: bit.ly/41rdZp8 #LBBCMetsConf #BreastCancerAwareness #bcsm

#BreastCancer stage at diagnosis plays a critical role in determining survival outcomes. For patients with metastatic breast cancer, the 5-year relative survival rate is approximately 30%. This underscores the significant unmet need for effective treatments for advanced and metastatic breast cancer. #bcsm #CancerResearch

February marks #NationalCancerPreventionMonth — a time to focus on empowering patients with evidence-based guidance on cancer prevention. Research shows that approximately 40% of cancers in the US are associated with modifiable risk factors, including nearly 20% linked to excess body weight, dietary patterns, alcohol use, and physical activity levels. #HCPs play a key role in raising awareness and supporting patients in adopting healthy lifestyle changes that may help reduce their cancer risk. Small, sustainable steps can have a meaningful impact. #CancerPrevention #HCPsForPrevention

The BCL6 transcriptional repressor is a master regulator of multiple cellular processes. When deregulated, BCL6 can be an oncogenic driver leading to lymphomagenesis. Learn about a recruiting clinical trial for an investigational #PROTAC BCL6 degrader here: http://bit.ly/3ND23rW #Hematology #lymsm